BioPharmSignal logoBioPharmSignal

Biotech News

Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

Adaptive Biotechnologies (ADPT)Adaptive BiotechnologiesConference / presentation

SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating

Related news

ADPTAdaptive Biotechnologies2026-07-29 20:05 EST

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

LUNGPulmonx2026-07-28 20:05 EST

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

ADPTAdaptive Biotechnologies2026-07-09 20:05 EST

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

IARTIntegra LifeSciences2026-06-15 12:30 EST

Integra LifeSciences to Present at the 2026 Truist Securities MedTech Conference

TMCITreace Medical Concepts2026-06-11 20:05 EST

Treace to Present at the Sidoti Small Cap Conference

IRIXIRIDEX2026-06-09 20:05 EST

Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference

PRCTPROCEPT BioRobotics2026-08-17 12:00 EST

PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026

CVRXCVRx2026-07-28 12:30 EST

CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference

ICUSeaStar Medical2026-06-22 12:45 EST

SeaStar Medical to Present at Upcoming Investor Summit Conference

PLSEPulse Biosciences2026-07-30 20:05 EST

Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference

View all latest news

Adaptive Biotechnologies

Adaptive Immune-System Platform Adaptive Biotechnologies develops clinical products by decoding the genetics of the adaptive immune system. Its proprietary platform measures immune-receptor sequences at scale to support disease monitoring, drug development and the discovery of immune-based therapeutics. Minimal Residual Disease The...

Recent company news

ADPTAdaptive Biotechnologies2026-07-29 20:05 EST

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

ADPTAdaptive Biotechnologies2026-07-09 20:05 EST

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

ADPTAdaptive Biotechnologies2026-06-30 12:30 EST

Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial

ADPTAdaptive Biotechnologies2026-06-17 10:00 EST

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

ADPTAdaptive Biotechnologies2026-06-15 20:10 EST

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

Stock data

Close
25.99 USD
Market cap
2.42B USD
Exchange
NASDAQ
Sector
MedTech
Location
United States